# Pliant Therapeutics (PLRX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/PLRX
## Company Profile
- Ticker: PLRX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 1.05 USD
- Market cap: 71827488.83999999 USD
- Last updated: 2026-08-05
## Business Overview
### Integrin-Targeted Drug Discovery
Pliant Therapeutics is a clinical-stage biotechnology company developing therapies that modulate integrin-mediated biological pathways. Its current development focus has shifted toward oncology and immune regulation.
### PLN-101095
PLN-101095 is an antibody targeting integrin αvβ8, a mechanism intended to alter the tumor microenvironment and improve antitumor immune activity. Early clinical work has evaluated the candidate in checkpoint-inhibitor-refractory solid tumors.
### FORTIFY Expansion Study
The Phase 1b FORTIFY study is evaluating PLN-101095 across indication-specific cohorts, including non-small cell lung cancer, clear-cell renal-cell carcinoma and melanoma. This trial is intended to define activity in selected tumors and guide subsequent development.
## Why The Stock Is Moving

As of Aug 5, 2026, PLRX was little changed and closed at $1.05. No new same-company headline was identified in the current news window.

## Future Catalysts

- Near-term attention for Pliant Therapeutics is likely to stay on PLN-101095. The current setup is really about First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095.... That is where the next meaningful signal is most likely to come from.

## Drug Assets

- PLN-101095

## Recent News
- 2026-07-13 12:30 EST — [Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-names-flavia-borellini-ph-d-and-robert-iannone-m-d-m-s-c-e-t-22eb831f) — Source: Pliant Therapeutics
- 2026-05-21 21:30 EST — [Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting) — Source: Pliant Therapeutics
- 2026-05-11 20:05 EST — [Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-first-quarter-2026-financial-results) — Source: Pliant Therapeutics
- 2026-05-06 12:30 EST — [Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-to-participate-in-the-rbc-capital-markets-global-healthcare-conference) — Source: Pliant Therapeutics
- 2026-04-30 12:30 EST — [Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-first-patient-dosed-in-fortify-the-phase-1b-indication-expansion-trial-evaluating-pln-101095-in-patients-with-ici-refractory-solid-tumors) — Source: Pliant Therapeutics